Praxis Precision Medicines (PRAX) News
NASDAQ: PRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
300.43-10.47 (-3.37%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRAX news summary
We found 39 recent headlines mentioning Praxis Precision Medicines (PRAX): 4 in the past week and 12 in the past 30 days, most often from Seeking Alpha, Nasdaq, GlobeNewswire. For price context, PRAX is down 3.37% at $300.43. The most recent story, "Praxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)", was published by Seeking Alpha on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Praxis Precision Medicines headlines
- Praxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)Seeking Alpha
- Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptSeeking Alpha
- Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)Seeking Alpha
- Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor DayDetailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027GlobeNewswire
- Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptSeeking Alpha
- Praxis Precision Medicines, Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory UpdatesPraxis Precision Medicines, Inc. reported its financial results for the third quarter ended September 30, 2026, with cash, cash equivalents and marketable securities of approximately $1.3 billion.…Nasdaq
- Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40Seeking Alpha
- Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40Seeking Alpha
- Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsFDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoingGlobeNewswire
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company,…GlobeNewswire
- Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference ParticipationCompany to host an in-person and virtual Investor Day on November 12, 2026 Company to host an in-person and virtual Investor Day on November 12, 2026GlobeNewswire
- UBS Initiates Coverage of Praxis Precision Medicines with BuyFintel reports that on October 15, 2026, UBS initiated coverage of Praxis Precision Medicines (NASDAQGS:PRAX) with a Buy recommendation. On the same day, HC Wainwright & Co. reiterated its Buy rating…Nasdaq
- JP Morgan Initiates Coverage of Praxis Precision Medicines at OverweightFintel reports that on October 16, 2026, JP Morgan initiated coverage of Praxis Precision Medicines (NASDAQGS:PRAX) with a Overweight recommendation.The stock closed at $241.78 on October 16, 2026,…Nasdaq
- Notable Monday Option Activity: PSIX, UVE, PRAXAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Power Solutions International Inc (Symbol: PSIX), where a total of 2,200 contracts have…NasdaqPSIX, UVE, PRAX
- Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)Seeking Alpha
- Praxis (PRAX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearVertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.NasdaqVRTX, AMLX, BBIO, PRAX
- Praxis: Commercial Launch Could Smash Expectations (Video)Seeking Alpha
- Show Me The Money: After An 800%+ Gain, PRAX Enters A High-Stakes Stretch(RTTNews) - With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision neuroscience…Nasdaq
- Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Praxis Precision Medicines Q2 Earnings Call HighlightsPraxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and…Nasdaq
- Praxis Precision Medicines: Priced For Half Of What I Think It's WorthSeeking Alpha
- FDA Extends Praxis' Relutrigine NDA Review; New PDUFA Date Set For December 27,2026(RTTNews) - Praxis Precision Medicines, Inc. (PRAX), a clinical-stage neuroscience biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period…Nasdaq
- Praxis 'Strong Buy': PDUFA In Early 2027 For Ulixacaltamide And BTD ElsunersenSeeking Alpha
- Praxis Gains After FDA Grants Breakthrough Therapy Designation To Elsunersen For SCN2A-DEE(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) rose in trading after the U.S. FDA granted Breakthrough Therapy Designation to Elsunersen for the treatment of seizures associated with SCN2A…Nasdaq
- Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaPRAX, GS
- Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential TremorSeeking Alpha
- Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE(RTTNews) - Wedbush Cuts Praxis Price Target to $162 After POWER1 MissNasdaq
- Stock Indexes Post New Record Highs Amid AI EnthusiasmThe S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.45%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.48%. June E-mini…NasdaqMSTR, DE, CARR, ADI
- Stocks Push Higher on US Labor Market Strength and AI SpendingThe S&P 500 Index ($SPX ) (SPY ) today is up +0.24%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.29%. June E-mini S&P futures…NasdaqMSTR, ADI, GLXY, ALV
- Stocks Pressured by Uncertainty of US-Iran Ceasefire ProspectsThe S&P 500 Index ($SPX ) (SPY ) today is down -0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.33%. June E-mini S&P…NasdaqAMAT, GOOGL, AVGO, INTU
- Tuesday Sector Laggards: Application Software, Biotechnology StocksIn trading on Tuesday, application software shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of ODDITY Tech, down about 30.3% and shares of Verra…NasdaqODD, VRRM, GLSI, PRAX
- Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptSeeking AlphaPRAX, BAC
- Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion PotentialSeeking Alpha
- Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha
- Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call TranscriptSeeking Alpha
- Praxis: Priced For Perfection Heading Into 2026Seeking Alpha